SELLAS doses first patient in study of GPS and KEYTRUDA® combination
Category: #health  By Mateen Dalal  Date: 2019-08-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

SELLAS doses first patient in study of GPS and KEYTRUDA® combination

The trial involves patients diagnosed with acute myeloid leukemia and colorectal, ovarian, triple negative breast and small cell lung cancers.

SELLAS Life Sciences Group, Inc., a biopharmaceutical company focusing on the development of cancer immunotherapies to address a varied cancer indications, has reportedly announced the dosing of the first patient for its Phase 1/2 open-label trial of GPS combined with KEYTRUDA, Merck’s anti-PD-1 therapy, to patients diagnosed with WT1-positive advanced cancers including hematologic and solid tumor malignances.

According to Angelos M. Stergiou, President and CEO at SELLAS, the study facilitates enhancement of safety and activity portfolio of GPS coupled with anti – PD-1 therapies, specifically combined with KEYTRUDA in several malignances, following initial combination clinical data with OPDIVO. Additionally, the WT1 immunotherapeutic, GPS, together with anti PD-1 immunotherapy agents may prove beneficial in the treatment of cancer, he further claimed.

As per a statement by the company, the co-principal investigators of the study are - Richard Maziarz, MD and Medical Director of the Adult Bone Marrow Stem Cell Transplant and Cellular Therapy at Knight Cancer Institute, and Roisin O’Cearbhaill, M.D., the Assistant Attending Physician in Gynecological Medical Oncology Service for Memorial Sloan Kettering Cancer Center.

Reportedly, the first clinical data from the study will be available by the first quarter of 2020.

SELLAS Life Sciences Group, Inc. is a biopharma-based company focusing on the cancer immunotherapeutics for a wide range of cancer related symptoms. The company’s leading product, GPS has been licensed from Memorial Sloan Kettering Cancer Centre in the U.S. and attacks the Wilms Tumor 1 protein that is vividly present in numerous types of tumors.

The trial is taking place across 20 states in the U.S. and would involve approximately 90 patients. Initially, the study will evaluate patients diagnosed with ovarian cancer and colorectal cancer followed by patients with acute myeloid leukemia, who cannot undergo stem cell transplant and those who cannot attain deeper morphological response than partial on hypomethylating agents, as well as patients with triple negative breast cancer and small cell lung cancer.

 

Source Credits : https://www.sellaslifesciences.com/investors/news/News-Details/2019/SELLAS-Advances-Galinpepimut-S-GPS-in-Combination-with-KEYTRUDA-pembrolizumab-Program-with-Dosing-of-First-Patient-in-Phase-12-Basket-Study/default.aspx

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
Telenor to sell stake in Myanmar's Wave Money for $53 Mn to Yoma
By Mateen Dalal

Telenor Group, an international provider of tele, data and media communication services, has reportedly agreed to sell its 51% stake in Myanmar's Wave Money, a provider of digital payment service, for $53 million to Yoma MFS Holdings, a subsidiar...

Alkem to launch state-of-the-art technology to treat DFU in India
Alkem to launch state-of-the-art technology to treat DFU in India
By Mateen Dalal

Alkem Laboratories Ltd. (Alkem), an Indian multinational pharmaceutical company, has reportedly launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on an innovative technology of...

Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
Bank of America unveils new drive-thru ATM; shuts another in Bethlehem
By Mateen Dalal

According to Andy Aldridge, Bank of America Spokesperson, the financial institutiThe Bank of America Corporation, an American multinational investment bank and financial services, has now opened up a new place for clients in North Bethlehem who are l...